CRVO CervoMed Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CRVO

Price (delayed)

$2.51

Market cap

$37.95M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.22

Enterprise value

$15.49M

?
Relative Growth: Rel. Growth: 5
Relative Strength: Rel. Strength: 5
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 22

Diffusion Pharmaceuticals Inc. is a biopharmaceutical company that has historically focused on developing novel therapies that may enhance the body’s ability to deliver oxygen to areas where it is needed ...

Highlights
The company's quick ratio has surged by 186% QoQ and by 6% YoY
The company's equity has surged by 116% QoQ but it fell by 31% YoY
The revenue has shrunk by 96% YoY and by 84% QoQ
CervoMed's gross profit has plunged by 96% YoY and by 84% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.diffusionpharma.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of CRVO

CRVO stock price

How has the CervoMed stock price performed over time
Intraday
-0.79%
1 week
2.87%
1 month
-4.2%
1 year
-69.54%
YTD
-68.23%
QTD
-19.03%

Financial performance

How have CervoMed's revenue and profit performed over time
Revenue
$331,295
Gross profit
$331,295
Operating income
-$31.16M
Net income
-$30.35M
Gross margin
100%
Net margin
-9,160.9%
The revenue has shrunk by 96% YoY and by 84% QoQ
CervoMed's gross profit has plunged by 96% YoY and by 84% from the previous quarter
CRVO's net income is down by 34% YoY
CRVO's operating income is down by 27% year-on-year

Price vs fundamentals

How does CRVO's price correlate with its fundamentals

Growth

What is CervoMed's growth rate over time

Valuation

What is CervoMed stock price valuation
P/E
N/A
P/B
1.01
P/S
77.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
46.74
CervoMed's EPS has decreased by 23% YoY
The company's equity has surged by 116% QoQ but it fell by 31% YoY
The P/B is 68% below the 5-year quarterly average of 3.2 and 65% below the last 4 quarters average of 2.9
The stock's price to sales (P/S) is 119% more than its last 4 quarters average of 35.8
The revenue has shrunk by 96% YoY and by 84% QoQ

Efficiency

How efficient is CervoMed business performance
The return on equity has dropped by 164% year-on-year and by 15% since the previous quarter
The ROA has plunged by 139% YoY and by 14% from the previous quarter
The company's return on invested capital has shrunk by 85% QoQ

Dividends

What is CRVO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRVO.

Financial health

How did CervoMed financials performed over time
The company's quick ratio has surged by 186% QoQ and by 6% YoY
The current ratio has soared by 155% from the previous quarter and by 4.5% YoY
The debt is 100% less than the equity
The company's equity has surged by 116% QoQ but it fell by 31% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.